Lacrimal Devices Market Size, Share and Trends 2024 to 2034

Lacrimal Devices Market Size and Forecast 2024 to 2034

The global lacrimal devices market size is projected to be worth around USD 238.24 million by 2034 from USD 165.19 million in 2024, at a CAGR of 3.73% from 2024 to 2034. The North America lacrimal devices market size reached USD 57.33 million in 2023. increasing prevalence of eye disorders, easy procedures for lacrimal treatment, and advanced technologies in lacrimal devices contribute to the growth of the market.

Lacrimal Devices Market Key Takeaways

• North America dominated the lacrimal devices market with he highest market share of 36% in 2023.
• Europe held the second-largest share of the market in 2023.
• By product, the stents segment dominated the market in 2023.
• By product, the incubation sets segment is expected to be the fastest-growing during the forecast period.
• By application, the dry eye segment is expected to have lucrative growth during the forecast period.
• By end-use, the hospital segment dominated the lacrimal devices market in 2023.
• By end-use, the ophthalmic clinics segment is anticipated to have significant growth during the forecast period.

U.S. Lacrimal Devices Market Size and Growth 2024 to 2034

The U.S. lacrimal devices market size was exhibited at USD 40.13 million in 2023 and is projected to be worth around USD 61.31 million by 2034, poised to grow at a CAGR of 3.92% from 2024 to 2034.

North America dominated the lacrimal devices market in 2023. The increasing prevalence of eye disorders and the availability of eye-related advanced technology products help the market growth in the North American region. Increasing awareness related to many secure eye disease treatments, the presence of key market players, rising disposable income, and increasing patient outcomes boost market growth. The United States is the leading country in the growth of the market in the North American region due to high healthcare investment and a robust medical industry.

• In January 2022, in Canada, ‘Cequa’ (cyclosporine ophthalmic solution 0.09 percent w/v), a new treatment for dry eye disease, a calcineurin inhibitor immunomodulator, was launched by a wholly owned subsidiary of Mumbai-based drug major, Sun Pharma Canada, Inc.

According to a report from the Dry Eye Directory Statistics in 2023, approximately 16.7 million people to 50.2 million people in America have DED or dry eye disease, and this number is increasing in both old adults and young.

Europe held the second-largest share of the lacrimal devices market in 2023. Germany is the leading country for the growth of the market in the European region. Enhanced regulatory environment for eye-related surgical devices and rising awareness in the population for eye-related disorders treatments. To serve patients effectively, companies have well-organized direct channel partnerships with ophthalmic clinics and hospitals.

• In August 2023, a biopharmaceutical company focusing on first and best-in-class ocular therapeutics, Novaliq GmbH, announced that the EMA (European Medicine Agency) has accepted MAA (marketing authorization acceptance) for ciclosporin ophthalmic solution (CyclASol) for regulatory review.

NOVALIQ’s IP Portfolio

EyeSol Technology: Strong established IP-Protection- allows composition of matter IP MEIBO and VEVYE:4+ Orange Book listable patents for each product in the US and FTO.

44 patent families with greater than 180 granted patents

• Spanning the full spectrum from
• SFA- production to indication

Market Overview

The lacrimal devices market is significantly growing due to rising awareness and diagnosis of ophthalmic disorders across many age groups. Lacrimal devices are physiological systems that contain orbital structures to produce tears and drainage. With the increasing prevalence of eye-related diseases, the demand for innovative lacrimal devices like irrigation systems, punctual plugs, and lacrimal stents, continuously rising. The lacrimal devices are the tiny helpers which play a significant role in maintaining eye health and comfort. As the old population grows, eye-related health issues will also grow, which will increase demand for lacrimal devices.

Lacrimal Devices Market Growth Factors

• The lacrimal devices are tiny helpers that play a significant role in maintaining eye health and comfort, producing tears.
• The functions of lacrimal devices include draining tears by the lacrimal punctum, washing away debris, lubricating the eye, and producing reflexive or emotional tears, which help the lacrimal devices market grow.
• It also includes functions like draining lacrimal fluid into the lacrimal sac through a series of canals, accumulating lacrimal fluid in the lacrimal lake, draining lacrimal fluid from the orbit, and promoting overall eye health.

What is the role of AI in the Lacrimal Devices?

The use of artificial intelligence (AI) in the lacrimal devices that are used to treat disorders related to tear production and drainage offers many significant benefits. The benefits include AI can accelerate research activities by analyzing large amounts of data to develop new therapies and identify innovative treatment targets for lacrimal disorders which helps to the growth of the lacrimal devices market. The benefits of the use of AI in lacrimal devices also include streamlined clinical workflow, enhanced patient monitoring, predictive analytics, personalized treatment plans, and improved diagnostic accuracy.

• For instance, in May 2022, a three-dimensional (3D) ‘mini-organs for human stem cells to model the tear ducts or lacrimal glands that are dysfunctional in Sjogren’s syndrome was developed in Japan by a research team.

Market Scope

Market Dynamics

Driver

Increasing prevalence of eye disorders

The increasing prevalence of eye disorders is driving the growth of the lacrimal devices market. The common causes of eye disorders include sickle cell disease, nutritional deficiencies, infectious diseases, retinal disorders, optic nerve disorders, refractive disorders, etc. Lacrimal devices are needed to maintain eye health and comfort. The lacrimal devices help in draining by lacrimal punctum, producing reflexive tears, accumulating lacrimal fluid in the lacrimal lake, washing away debris, lubricating the eye, etc.

Restraint

High side effects risks

The risks of side effects due to lacrimal devices may occur, which can hamper the growth of the lacrimal devices market. The risks of lacrimal devices include prominent facial scars, infection, excess bleeding, displacement of stent placed in the duct, abnormally fused tissue in the nose, inflammations like bacterial, viral, and fungal, drug-induced issues, post-surgical damage, etc. The increased senior population and adult age are associated with an increased risk of punctual and canalicular obstruction.

Opportunity

Enhanced product efficiency

The enhanced efficiency of lacrimal devices products can be an opportunity for the growth of the lacrimal devices market. Expanding therapeutic applications and advanced product development there are growth opportunities for the market. In addition, technological advancements in lacrimal devices sign growth opportunities in ophthalmology, helping leaders use their business strategies to meet developing healthcare necessities.

Product Insights

The stents segment dominated the lacrimal devices market in 2023. Lacrimal stents are small diameter tubes made from metal, plastics, or fabric that are placed in the nasolacrimal system to maintain patency. The common indications for using lacrimal stents include congenital blockage, which may seen in newborns, post-surgical, malignancy, infection, trauma, or other inflammatory diseases. Lacrimal stents help to keep the tear drainage pathway open, enabling tears to flow properly from eye to nose. The types of lacrimal stents include bi-canalicular stents and mono-canalicular stents. These factors help to the growth of the market. The lacrimal stents are designed for the treatment of epiphora, glaucoma, canalicular stenosis, and nasolacrimal duct obstruction and are also used for canalicular lacerations. Lacrimal stents are also called lacrimal intubation devices.

• In October 2022, a contralateral eye study investigated iStent vs Hydrus stent for glaucoma was provided by Mitch Shultz, MD, at AAO 2022.

Application Insights

The dry eye segment is expected to grow lucratively in the lacrimal devices market during the forecast period. Lacrimal devices like punctual plugs help reduce extra tear loss from the tear ducts in the eyes. They can also help to ensure that the tears have to stay in the eyes for longer. Excess moisture loss and tearing are the most common symptoms of dry eyes, along with burning, redness, and itchiness. Complications from untreated dry eye include difficulty driving, reading, and other things that require good vision, vision loss, corneal abrasions, ulcers, eye inflammation, eye irritation, etc., that need treatment, which helps the growth of the market.

The benefits of dry eye treatment with the help of lacrimal devices include it helps to regulate tear production by increasing tear production, reducing inflammation, preventing tears from draining or evaporating too quickly, and adding tears.

• In April 2024, the ‘SOFT PLUG Extended Duration 180 T-Tapered Plug’, which is a dry eye-targeted product, was launched by OASIS Medical, Inc. The company provides solution-based products for dry eye and surgical practices.

OASIS’s Punctal Plugs Include

• FORM FIT Hydrogel Canalicular Plugs
• SOFT PLUG Silicon Punctum Plugs
• SOFT PLUG Flow Control Plugs
• SOFT PLUG Collagen Intracanalicular Plugs
• SOFT PLUG Extended Duration Plugs

End Use Insights

The hospital segment dominated the lacrimal devices market in 2023. The presence of advanced technology, well-developed tools, and developed infrastructure contribute to the growth of the market. The presence of several nursing staff and doctors for efficient diagnosis and treatment for proper care boosts the market’s growth. The benefits of lacrimal devices in hospitals include access to cutting-edge care, eye health improvement, lower fees, etc.

• In August 2024, a leading network of eye care in India, Dr. Agarwal’s Eye Hospital, opened its new hospital facility and expanded in the city of Kakinada. The new hospital is situated at Bhanugudi Junction.

The ophthalmic clinics segment is anticipated to have significant growth during the forecast period. Ophthalmology is a surgical and clinical specialty in medicine that deals with the diagnosis and treatment of eye-related disorders, which helps the lacrimal devices market grow. The ophthalmic clinic offers complete eye care under one roof by using advanced surgical equipment and advanced technology. They can provide eye care for the most simple eye disorders and the most critical eye disorders.

• In June 2024, the Fernandez Hospital launched the Children’s Eye Clinic in collaboration with LVPEI (L V Prasad Eye Institutes) at their Necklace Road Clinic. The clinic aims to provide complete eye care services for children age group from 0-16 years.

Lacrimal Devices Market Companies

• Walsh Medical Devices Inc.
• JEDMED
• Braintree Scientific
• Kaneka Corporation
• Bess Medical Technology GmbH
• Rumex International Co
• Lacrimedics Inc.
• BVI
• Meddenium
• FCI Ophthalmic
• Gunther Weiss Scientific Glass

Recent Developments

• In May 2023, the first prescription drug approved by the FDA named Miebo drops for dry eye was launched by an eye care specialist Bausch and Lomb. The drug is used in treatment to directly target the evaporation of tears and addresses a remarkable unmet necessity for patients.
• In January 2024, in WAIEA, Hawaii, the Vevye ophthalmic solution for dry eye disease treatment was launched by Mark L. Baum, Chairman and CEO at Harrow. Vevye is preservative-free, twice daily 0.1% cyclosporine ophthalmic solution indicated for symptoms and signs of dry eye disorder.

Segments Covered in the Report

By Product

• Intubation Sets
• Tubes
• Stents
• Cannula & Spatula
• Dilator
• Punctal Plugs
• Others

By Application

• Dry Eye
• Glaucoma
• Epiphora
• Drainage Obstruction
• Lacrimal Gland Inflammation
• Others

By End-use

• Hospitals
• Ophthalmic Clinics
• Diagnostic Centers
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa